Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma
Open Access
- 1 May 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (9), 3485-3493
- https://doi.org/10.1158/1078-0432.ccr-04-1781
Abstract
Purpose: We examined the activity of gemcitabine against neuroblastoma in vitro and in vivo. In addition, we investigated the cellular mechanisms of high sensitivity to the agent in neuroblastoma cells. Experimental Design: We examined 11 neuroblastoma cell lines for sensitivity to gemcitabine and other chemotherapeutic agents used clinically for neuroblastoma. The in vivo sensitivity of neuroblastoma to gemcitabine was determined in xenograft models. Furthermore, the major metabolic enzymes of gemcitabine were assessed and compared in leukemia and carcinoma cells. Apoptosis and mitochondrial membrane potentials were also evaluated. Results: The IC50s for gemcitabine in 11 neuroblastoma lines ranged between 3 nmol/L and 4 μmol/L. The high activity of gemcitabine against neuroblastoma was confirmed in animal models. Interestingly, enzymes in neuroblastoma cells involved in the metabolism of deoxycytidine analogue have unique characteristics among solid tumors. The median of deoxycytidine kinase activity in neuroblastoma lines was similar to that in leukemia lines, which have low IC50s for cytarabine. Cytidine deaminase (CDA) activity in neuroblastoma was hardly detectable and significantly lower than that in carcinoma. The defect of CDA activity was associated with negative expression of mRNA. Furthermore, gemcitabine-induced apoptosis was observed irrespective of the caspase-8 status of neuroblastoma cells, which indicates that apoptosis depends on the mitochondrial pathway. Conclusions: Neuroblastoma is highly sensitive to gemcitabine. Although the cellular mechanism involved in sensitivity to gemcitabine is multifactorial, low CDA activity may contribute high sensitivity in neuroblastoma cells. These results suggest that clinical application of gemcitabine to the treatment of neuroblastoma is warranted.Keywords
This publication has 29 references indexed in Scilit:
- Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid TumorsJournal of Clinical Oncology, 2004
- Fractionated low‐dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high‐risk neuroblastomaCancer, 2004
- Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas StimulationPublished by Elsevier BV ,2004
- MYCN-mediated regulation of the MRP1 promoter in human neuroblastomaOncogene, 2004
- Cyclopentenyl cytosine primes SK‐N‐BE(2)c neuroblastoma cells for cytarabine toxicityInternational Journal of Cancer, 2002
- Phase I trial of gemcitabine (Gemzar®), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancerAnti-Cancer Drugs, 1999
- Deoxycytidine kinase mRNA Levels in leukemia cells with competitive polymerase chain reaction assayLeukemia Research, 1996
- Cloning of a Functional cDNA for Human Cytidine Deaminase (CDD) and Its Use as a Marker of Monocyte/Macrophage DifferentiationBiochemical and Biophysical Research Communications, 1993
- Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogsBiochemical and Biophysical Research Communications, 1991
- Purification and Properties of Cytidine Deaminase from Normal and Leukemic GranulocytesJCI Insight, 1974